AN2 Therapeutics Inc., a biopharmaceutical company focused on developing novel small molecule therapeutics, has reported its financial results for the first quarter of 2025. The company reported a net loss of $10.6 million for the quarter, which is an improvement from the $16.6 million net loss recorded in the same period of 2024. Research and Development (R&D) expenses for the first quarter of 2025 decreased to $7.7 million from $14.7 million in the first quarter of 2024, primarily due to reduced clinical trial expenses, personnel-related expenses, and costs associated with the termination of the EBO-301 clinical study and corporate restructuring activities. General and Administrative (G&A) expenses were slightly higher at $3.8 million compared to $3.6 million in the same period of 2024, due to increased professional services expenses. Interest income for the quarter was $0.9 million, down from $1.7 million in the first quarter of 2024, attributed to lower cash, cash equivalents, investment balances, and interest rates in 2025 compared to 2024. The company had cash, cash equivalents, and investments totaling $78.5 million as of March 31, 2025, and anticipates that its current cash position will sustain operations into 2028, extending the previous guidance of sustaining operations through 2027. In terms of business operations, AN2 Therapeutics is advancing its pipeline with high-impact clinical programs, including a Phase 1 clinical study for its product candidate AN2-502998, which has curative potential for chronic Chagas disease. The company also continues to pursue non-dilutive funding for global health initiatives, including tuberculosis and malaria, funded by the Gates Foundation.